(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

NEUROFORM

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

NEUROFORM

ST13

US500000076381617

Class

10

Filing

76381617

Registration

2782837

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

35

Latest update

02/04/2025

Trademark type

Word

Nice classes

10

Filing date

03/13/2002

Registration date

11/11/2003

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

01/14/2025

Last transaction

02/04/2025

Responsible office

United States Patent and Trademark Office

Status code

800

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

11/26/2002

First use in commerce

11/26/2002

Drawing code

1

Owner type

77

Owner location

CARRIGTWOHILL, COUNTY CORK, IE

Examiner

FRENCH, CURTIS

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

STRYKER EUROPEAN OPERATIONS LIMITED
SciMed Life Systems, Inc.
STRYKER EUROPEAN HOLDINGS LLC
S. C. (pessoa física)
BOSTON SCIENTIFIC SCIMED, INC.
STRYKER NV OPERATIONS LIMITED

Representatives

Eugene J. Rath III Flynn Thiel, P.C.

Technical classification

Nice Classes

Class 10

Vienna Codes

No Vienna codes available.

Goods and services

Class 10

medical stents for neurovascular applications

Publications

History of USPTO decisions and trademark events.

35 publications found

NA89

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

01/14/2025

RNL2

REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)

01/14/2025

89AG

REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

01/14/2025

EROP

TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED

01/09/2025

PR89

POST REGISTRATION ACTION MAILED - SEC. 8 & 9

07/26/2024

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

07/26/2024

E89R

TEAS SECTION 8 & 9 RECEIVED

05/02/2024

REM2

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

11/11/2022

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

06/18/2020

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

06/10/2020

ASCK

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

07/29/2015

NA89

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

11/29/2013

RNL1

REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)

11/29/2013

89AG

REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED

11/29/2013

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

11/29/2013

89AF

REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED

11/11/2013

E89R

TEAS SECTION 8 & 9 RECEIVED

11/11/2013

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

06/15/2011

C15A

REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

05/13/2010

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

05/13/2010

E815

TEAS SECTION 8 & 15 RECEIVED

04/28/2010

CORV

REVIEW OF CORRESPONDENCE COMPLETE

09/18/2006

MAIL

PAPER RECEIVED

03/23/2006

R.PR

REGISTERED-PRINCIPAL REGISTER

11/11/2003

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

09/06/2003

DOCK

ASSIGNED TO EXAMINER

08/29/2003

CFIT

CASE FILE IN TICRS

08/28/2003

SUPC

STATEMENT OF USE PROCESSING COMPLETE

08/01/2003

IUAF

USE AMENDMENT FILED

07/10/2003

EISU

TEAS STATEMENT OF USE RECEIVED

07/10/2003

NOAM

NOA MAILED - SOU REQUIRED FROM APPLICANT

01/14/2003

PUBO

PUBLISHED FOR OPPOSITION

10/22/2002

NPUB

NOTICE OF PUBLICATION

10/02/2002

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

07/24/2002

DOCK

ASSIGNED TO EXAMINER

07/24/2002

Continuous trademark protection

Get notified about every new filing that threatens NEUROFORM or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.